IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Lessened by KBC Group NV

KBC Group NV trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 88,363 shares of the company's stock after selling 12,585 shares during the period. KBC Group NV owned about 0.11% of IDEXX Laboratories worth $36,534,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. International Assets Investment Management LLC increased its stake in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Clearbridge Investments LLC increased its stake in IDEXX Laboratories by 696.0% in the 2nd quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock valued at $171,891,000 after purchasing an additional 308,493 shares in the last quarter. Seilern Investment Management Ltd purchased a new position in IDEXX Laboratories in the 4th quarter valued at approximately $113,104,000. Finally, Vontobel Holding Ltd. increased its stake in IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock valued at $111,229,000 after purchasing an additional 213,731 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 2.3 %

Shares of NASDAQ IDXX traded down $9.66 during midday trading on Tuesday, reaching $417.86. 1,333,799 shares of the company's stock were exchanged, compared to its average volume of 684,047. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The stock has a market capitalization of $34.22 billion, a PE ratio of 40.30, a price-to-earnings-growth ratio of 3.63 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The business's fifty day moving average price is $423.89 and its two-hundred day moving average price is $455.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the firm earned $2.53 earnings per share. Analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on IDXX shares. Barclays dropped their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Piper Sandler restated a "neutral" rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Finally, StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $523.86.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.